Mangalam Drugs

Which are the latest news on Mangalam Drugs?

Why is Mangalam Drugs and Organics Ltd falling/rising?

As of 05-Sep, Mangalam Drugs and Organics Ltd's stock price is at 30.35, down 0.43%. The stock has shown a trend reversal with a 4.83% decline over the past week, despite a 10.89% rise in the last month, and a concerning 60.77% drop over the past year.

As of 05-Sep, Mangalam Drugs and Organics Ltd's stock price is currently at 30.35, reflecting a decrease of 0.13, or 0.43%. The stock has experienced a trend reversal, having fallen after two consecutive days of gains. Over the past week, the stock has declined by 4.83%, while the benchmark Sensex has only decreased by 0.97%. <BR><BR>Despite a positive performance over the past month, where the stock rose by 10.89% compared to a 2.44% drop in the Sensex, the year-to-date performance shows a modest gain of 10.00 against a significant decline of 10.21% in the benchmark. However, the stock's long-term performance is concerning, with a 60.77% drop over the past year and a staggering 79.16% decline over the last five years, while the Sensex has only decreased by 5.21% and increased by 31.63% over the same period.<BR><BR>Additionally, there is a notable decline in investor participation, as evidenced by a 40.5% drop in delivery volume on September 3rd compared to the five-day average. This suggests a decrease in trading activity and interest in the stock. Although the stock is trading above its 20-day, 50-day, and 100-day moving averages, it is below the 5-day and 200-day moving averages, indicating mixed signals regarding its short-term performance. Overall, these factors contribute to the current downward movement in the stock price of Mangalam Drugs and Organics Ltd.

Who are in the management team of Mangalam Drugs?

The management team of Mangalam Drugs includes Govardhan M Dhoot (Chairman & Managing Director), Brijmohan Dhoot (Whole-time Director), Rukmesh P. Dhandhania, Nidhi S. Mundada, and Praveen Saxena (Independent Directors), Jayant Barde (Company Secretary & Compliance Officer), and Rakesh K. Milwani (Director). They oversee the company's operations and strategic direction.

The management team of Mangalam Drugs includes the following individuals:<BR><BR>1. **Govardhan M Dhoot** - Chairman & Managing Director<BR>2. **Brijmohan Dhoot** - Whole-time Director<BR>3. **Rukmesh P. Dhandhania** - Independent Director<BR>4. **Nidhi S. Mundada** - Independent Director<BR>5. **Praveen Saxena** - Independent Director<BR>6. **Jayant Barde** - Company Secretary & Compliance Officer<BR>7. **Rakesh K. Milwani** - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Mangalam Drugs do?

Mangalam Drugs and Organics Ltd manufactures organic and inorganic chemicals in the Pharmaceuticals & Biotechnology sector. As of June 2026, it reported net sales of 57 Cr and a net loss of 8 Cr, with a market cap of INR 50 Cr.

Overview: <BR>Mangalam Drugs and Organics Ltd is a company engaged in the manufacture of organic and inorganic chemicals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>The company was initially incorporated as 'Advent Pharma Private Limited' in 1972, changed its name to Mangalam Drugs and Organics Private Limited in 1997, and later became a Public Limited Company in 2001. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 57 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -8 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 50 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.02 <BR>Return on Equity: -43.09% <BR>Price to Book: 0.49<BR><BR>Contact Details: <BR>Address: 3rd Floor Rupam Building, 239 P D Mello Road Mumbai Maharashtra : 400001 <BR>Tel: 91-22-22616200/6300/8787 <BR>Email: contactus@mangalamdrugs.com <BR>Website: http://www.mangalamdrugs.com

Who are the peers of the Mangalam Drugs?

Peers of Mangalam Drugs include Phaarmasia, Shelter Pharma, and Biofil Chemicals, among others. Mangalam Drugs has below-average growth and management risk, with a 1-year return of -57.20%, higher than Rajnish Wellness but significantly lower than Phaarmasia's 192.54%.

Peers: The peers of Mangalam Drugs are Phaarmasia, Shelter Pharma, Biofil Chemicals, Vasundhara Rasy., Parmax Pharma, Kabra Drugs, Rajnish Wellness, Vivo Bio Tech, Vilin Bio Med, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Biofil Chemicals, Vasundhara Rasy., and Rajnish Wellness, and the rest. Below Average management risk is noted at Phaarmasia, Mangalam Drugs, Parmax Pharma, Kabra Drugs, Vivo Bio Tech, Vilin Bio Med, and Ajooni Biotech. Growth is rated as Good at Shelter Pharma and Ajooni Biotech, Average at Phaarmasia and Vilin Bio Med, while Below Average growth is seen at Mangalam Drugs, Biofil Chemicals, Vasundhara Rasy., Parmax Pharma, Kabra Drugs, Rajnish Wellness, and Vivo Bio Tech. Capital Structure is Excellent at Shelter Pharma, Good at Biofil Chemicals and Vasundhara Rasy., and Below Average at Phaarmasia, Mangalam Drugs, Parmax Pharma, Kabra Drugs, Rajnish Wellness, Vivo Bio Tech, Vilin Bio Med, and Ajooni Biotech.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Phaarmasia at 192.54%, while the lowest is Rajnish Wellness at -61.17%. Mangalam Drugs has a 1-year return of -57.20%, which is higher than Rajnish Wellness but significantly lower than Phaarmasia. Additionally, Kabra Drugs, Rajnish Wellness, Vivo Bio Tech, and Vilin Bio Med have negative six-month returns.

How big is Mangalam Drugs?

As of 31st August, Mangalam Drugs and Organics Ltd has a market capitalization of 50.00 Cr and reported Net Sales of 232.33 Cr with a Net Profit loss of 38.25 Cr over the latest four quarters.

As of 31st August, Mangalam Drugs and Organics Ltd has a market capitalization of 50.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 232.33 Cr. However, it experienced a loss of 38.25 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 148.98 Cr and Total Assets were reported at 366.42 Cr.

Should I buy, sell or hold Mangalam Drugs and Organics Ltd?

When is the next results date for Mangalam Drugs and Organics Ltd?

The next results date for Mangalam Drugs and Organics Ltd is 12 August 2026.

The next results date for Mangalam Drugs and Organics Ltd is scheduled for 12 August 2026.

Are Mangalam Drugs and Organics Ltd latest results good or bad?

Mangalam Drugs and Organics Ltd's latest results are concerning, with a net profit loss of ₹13.42 crores in Q4 FY26, marking the fourth consecutive quarter of losses. Despite a slight improvement in net sales, the company faces significant operational challenges, reflected in a negative operating margin and a return on equity of -15.52%.

The latest results for Mangalam Drugs and Organics Ltd are quite concerning. In Q4 FY26, the company reported a net profit loss of ₹13.42 crores, which is a staggering decline of 22,466.67% year-on-year. This marks the fourth consecutive quarter of losses, totaling ₹44.41 crores for the fiscal year.<BR><BR>While net sales for Q4 FY26 were ₹67.29 crores, showing a 15.26% improvement from the previous quarter, this still represents a 7.54% decline compared to the same quarter last year. The operating margin has turned negative at -8.35%, a significant drop from a positive 13.60% in Q4 FY25. <BR><BR>Additionally, the company's return on equity (ROE) has plummeted to -15.52%, indicating severe operational and financial distress. The overall financial performance suggests that the company is struggling with fundamental issues that extend beyond typical market challenges. <BR><BR>In summary, the results indicate a deteriorating situation for Mangalam Drugs, characterized by significant losses, declining sales, and negative profitability metrics.

Is Mangalam Drugs overvalued or undervalued?

As of November 21, 2025, Mangalam Drugs is considered a risky investment due to its negative PE ratio of -3.75, ROE of -13.07%, and an EV to EBITDA ratio of 13.75, significantly underperforming against peers like Sun Pharma and Cipla, and has a year-to-date return of -60.33% compared to the Sensex's 9.08%.

As of 21 November 2025, the valuation grade for Mangalam Drugs has moved from very attractive to risky, indicating a significant deterioration in its financial standing. The company is currently considered overvalued based on its negative PE ratio of -3.75 and a ROE of -13.07%. Additionally, the EV to EBITDA ratio stands at 13.75, which is notably higher than some peers, suggesting that investors are paying a premium despite the company's poor performance.<BR><BR>In comparison to its peers, Mangalam Drugs' valuation metrics are starkly unfavorable. For instance, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla, which is rated attractive, has a PE of 22.45 and an EV to EBITDA of 15.88. The stark contrast in these ratios highlights Mangalam Drugs' overvaluation in the current market context. Furthermore, the company's stock has significantly underperformed against the Sensex, with a year-to-date return of -60.33% compared to the Sensex's 9.08%, reinforcing the notion that Mangalam Drugs is not a favorable investment at this time.

How has been the historical performance of Mangalam Drugs?

Mangalam Drugs showed significant financial improvement from March 2024 to March 2025, with net sales decreasing to 318.23 Cr but operating profit rising to 36.33 Cr, leading to a profit after tax of 6.72 Cr. The company also experienced a strong increase in cash flow from operating activities, indicating a recovery and growth trajectory.

Answer:<BR>The historical performance of Mangalam Drugs shows a significant improvement in financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Mangalam Drugs reported net sales of 318.23 Cr, a decrease from 368.59 Cr in the previous year. Total operating income mirrored this trend, remaining at 318.23 Cr, while total expenditure excluding depreciation fell to 282.40 Cr from 351.20 Cr. This reduction in costs contributed to an operating profit (PBDIT) of 36.33 Cr, up from 17.49 Cr, reflecting a notable increase in operating profit margin from 4.73% to 11.28%. The company transitioned from a loss of 11.07 Cr in profit before tax in March 2024 to a profit of 4.79 Cr in March 2025, with profit after tax also improving from a loss of 9.07 Cr to a profit of 6.72 Cr. Earnings per share rose to 4.25 from a negative 5.73. On the balance sheet, total liabilities increased to 366.42 Cr from 333.70 Cr, while shareholder's funds grew to 148.98 Cr from 135.79 Cr. The cash flow from operating activities surged to 42.00 Cr compared to 3.00 Cr in the prior year, indicating a strong operational performance. Overall, these metrics illustrate a recovery and growth trajectory for Mangalam Drugs in the latest fiscal year.

What is the technical trend for Mangalam Drugs?

As of May 22, 2025, Mangalam Drugs shows a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mildly bullish indicators from MACD, KST, and OBV, while the stock has significantly underperformed the Sensex over the past year.

As of 22 May 2025, the technical trend for Mangalam Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. The MACD on a weekly basis is mildly bullish, but the monthly perspective remains bearish, suggesting mixed signals. The KST and OBV on the weekly timeframe are mildly bullish, indicating some underlying strength, yet the overall trend remains cautious. The stock's performance over the past year shows a significant decline, underperforming the Sensex, which further supports the bearish outlook.

Who are the top shareholders of the Mangalam Drugs?

The top shareholders of Mangalam Drugs include Shri Jb Pharma Private Limited with 16.74%, individual investors with 44.55%, and two foreign institutional investors holding 0.47%. The highest public shareholder is Ashutosh Tapria at 1.91%, with 13.23% of promoter holdings pledged.

The top shareholders of Mangalam Drugs are primarily the promoters, with Shri Jb Pharma Private Limited holding the largest stake at 16.74%. Additionally, individual investors collectively own 44.55% of the shares. The company has two foreign institutional investors (FIIs) that hold a combined 0.47%. The highest public shareholder is Ashutosh Tapria, who owns 1.91% of the shares. It's worth noting that 13.2252% of the promoter holdings are pledged.

Has Mangalam Drugs declared dividend?

Yes, Mangalam Drugs and Organics Ltd declared a 5% dividend (0.5 per share) with an ex-date of December 21, 2017. However, recent performance shows no dividend returns over various periods, with total returns fluctuating significantly.

Mangalam Drugs and Organics Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 21 Dec 17<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -32.44%, the dividend return was 0%, resulting in a total return of -32.44%.<BR><BR>For the 1-year period, the price return was -20.09%, the dividend return was 0%, leading to a total return of -20.09%.<BR><BR>Over the 2-year period, the price return was -22.72%, with a dividend return of 0%, culminating in a total return of -22.72%.<BR><BR>In the 3-year period, the price return was -46.19%, the dividend return was 0%, resulting in a total return of -46.19%.<BR><BR>For the 4-year period, the price return was -40.39%, the dividend return was 0%, leading to a total return of -40.39%.<BR><BR>In the 5-year period, the price return was 32.79%, with a dividend return of 0%, resulting in a total return of 32.79%.<BR><BR>Overall, while Mangalam Drugs declared a dividend in the past, the recent performance shows no dividend returns in the last several periods, and the total returns have varied significantly, reflecting a challenging financial landscape.